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Abstract
Background: sFRP-3 is a soluble antagonist of Wnts, widely expressed in developing embryos. The Wnt gene family
comprises cysteine-rich secreted ligands that regulate cell proliferation, differentiation, organogenesis and oncogenesis of
different organisms ranging from worms to mammals. In the canonical signal transduction pathway Wnt proteins bind to
the extracellular domain of Frizzled receptors and consequently recruit Dishevelled (Dsh) to the cell membrane. In addition
to Wnt membrane receptors belonging to the Frizzled family, several other molecules have been described which share
homology in the CRD domain and lack the putative trans-membrane domain, such as sFRP molecules (soluble Frizzled
Related Protein). Among them, sFRP-3 was originally isolated from bovine articular cartilage and also as a component of the
Spemann organizer. sFRP-3 blocks Wnt-8 induced axis duplication in Xenopus embryos and binds to the surface of cells
expressing a membrane-anchored form of Wnt-1. Injection of sFRP-3 mRNA blocks expression of XMyoD mRNA and leads to
embryos with enlarged heads and shortened trunks.
Methodology/Principal Findings: Here we report that sFRP-3 specifically blocks EGF-induced fibroblast proliferation and
foci formation. Over-expression of sFRP-3 reverts EGF-mediated inhibition of hair follicle development in the mouse
ectoderm while its ablation in Xenopus maintains EGF-mediated inhibition of ectoderm differentiation. Conversely, over-
expression of EGF reverts the inhibition of somitic myogenesis and axis truncation in Xenopus and mouse embryos caused
by sFRP-3. In vitro experiments demonstrated a direct binding of EGF to sFRP-3 both on heparin and on the surface of CHO
cells where the molecule had been membrane anchored.
Conclusions/Significance: sFRP-3 and EGF reciprocally inhibit their effects on cell proliferation, differentiation and
morphogenesis and indeed are expressed in contiguous domains of the embryo, suggesting that in addition to their
canonical ligands (Wnt and EGF receptor, respectively) these molecules bind to each other and regulate their activities
during embryogenesis.
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Introduction
The Wnt gene family comprises cysteine-rich secreted ligands
that regulate cell proliferation, differentiation, organogenesis and
oncogenesis of different organisms ranging from worms to
mammals [1,2]. In the canonical pathway Wnts bind to the
extracellular domain of Frizzled receptors [3,4] and through
canonical b-catenin or Ca2+/PKC dependent pathways activates
Wnt target genes [5]. In addition to Frizzled receptors, four sFRP
(Soluble Frizzled Related Protein), sharing homology in the CRD
domain but lacking the putative trans-membrane domain have
been identified [6]. sFRP-3, also known as Frzb-1, was originally
isolated from bovine articular cartilage and also as a component of
the Spemann organizer [7]. sFRP-3 binds to the surface of cells
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expressing a membrane-anchored form of Wnt-1 and blocks Wnt-
8 induced axis duplication in Xenopus embryos [8]. Injection of
sFRP-3 mRNA blocks expression of XMyoD mRNA and leads to
embryos with enlarged heads and shortened trunks [8].
Recently, unforeseen cross-talks among different signaling
pathways have been shown to affect several cellular responses
both in embryogenesis and in oncogenesis. These interactions
occur both in the extra-cellular space (ligand-ligand interaction) at
the level of membrane receptors, and in the cytoplasm by second
messenger molecules, such as SMAD, that are shared by different
signaling pathways. In Drosophila, it is well known that Wg and
EGF together regulate several morphogenetic events such as
imaginal disc formation [9–11]. Whether this implies physical
interaction among the signaling molecules or members of their
signaling cascades is still unknown.
Here we show reciprocal inhibition of many biological activities
exerted by EGF and sFRP-3 that are expressed in contiguous
domains of both mesoderm and neuroectoderm and bind to each
other in vitro. Thus one cross-talk between the Wnt and the EGF
pathways is at the level of ligand binding in the extracellular space
and may regulate reciprocal activities during embryogenesis.
Results
sFRP-3 expression alters C3H10T1/2 fibroblasts
morphology and proliferation
When retrovirally over-expressed in C3H10T1/2 cells, that do
not express Wnts or sFRPs (see next paragraph for details), sFRP-3
affects their morphology and inhibits their proliferation. As shown
in Figure 1, cells expressing sFRP-3 appeared smaller than their
parental counterparts and projected several cytoplasm processes
(compare 1C with 1A). In addition sFRP-3 expression altered the
cytoskeleton, inducing stress fiber disorganization, membrane
ruffling, and filopodia (compare 1D with 1B and 1F). In contrast,
Wnt-1-over-expressing cells grew more densely as a monolayer,
forming bundles lined up in uniform directions (Fig. 1E). As
previously reported [12] Wnt-1-expressing cells proliferated faster
than parental cells, with an almost two-fold increase in plateau cell
density, while sFRP-3-expressing cells proliferated more slowly
showing a reduced plateau cell density (Fig. 1G). Flow cytometry
analysis revealed a significant accumulation of sFRP-3-expressing
cells in G0/G1 phase in comparison with control cells, while Wnt-
1-expressing cells exhibited a significant reduction of cells in the
G0/G1 phase (Fig. 1H; see quantification of these data in Table
S1).
Conditioned medium from sFRP-3-expressing, but not from
control cells, inhibited proliferation of Wnt-1 expressing but also of
control C3H10T1/2 fibroblasts (not shown).
sFRP-3 specifically inhibits EGF mediated proliferation of
C3H10T1/2 cells
C3H10T1/2 cells express few Wnts such as Wnt2, 2b, 4, 5, 5b,
and 9a at extremely low, basically background, level (0,0001% of
reference housekeeping genes, see Table S2) as demonstrated by
quantitative RT-PCR experiments performed on Wnt-pathway
PCR array (SuperArray Bioscience Corporation, see Materials
and Methods for details). Thus, sFRP-3 dependent inhibition of
C3H10T1/2 cells proliferation is not likely due to the inhibition of
a Wnts-mediated autocrine loop, also because other necessary
molecules of the Wnt pathway, such as Lef1, are not expressed in
these cells (Table S2). Since proliferation depends upon the action
of different mitogens present in the fetal calf serum (FCS), such as
EGF, FGF, PDGF, we investigated whether sFRP-3 could block
the mitogenic response mediated by any of these factors. To test
this hypothesis we exposed serum starved control and sFRP-3
expressing C3H10T1/2 cells to EGF (100 ng/ml), bFGF (10 ng/
ml), PDGF (0.4 nM) or HGF (20 ng/ml). As expected, control
C3H10T1/2 cells proliferate in response to any of these growth
factors, even though to a different extent (Fig. 2A). Interestingly,
sFRP-3 expressing cells were able to proliferate in response to all
growth factors like control cells, with the notable exception of EGF
(Fig. 2B), in presence of which they failed to proliferate, even when
present at the highest concentration (Fig. 2C–D). This data clearly
demonstrates that reduced proliferation of sFRP-3 expressing
C3H10T1/2 cells in high serum depends by the inability of these
cells to respond to serum EGF, and suggests a possible direct
interaction between sFRP-3 and EGF.
sFRP-3 inhibits the EGF-induced colony formation and
focal transformation of EGF-receptor over-expressing NIH
3T3 cells
To further investigate this unexpected finding, we assessed
whether other known biological activities of EGF might be blocked
by sFRP-3. We tested: 1) EGF induced oncogenic phenotype in
transformed cells; 2) EGF triggered transient increases in [Ca2+]i
in 3T3; 3) EGF inhibition of hair follicle appearance in explants of
embryonic ectoderm.
A clone (nu17) of NIH 3T3 cells that over-expresses the EGF
receptor [13,14] undergoes EGF-dependent focal transformation
and generates colonies in soft agar in the presence of EGF. As
expected, twenty days after plating, EGF induced the formation of
clearly visible colonies in agar, in a concentration-dependent way
(Fig. 3A, B). This effect was inhibited by incubation of cells in
sFRP-3-containing agar (Fig. 3C, D). The grade of inhibition
correlated with the percentage of sFRP-3 containing medium used
for agar preparation. The inhibitory effect of sFRP-3 was also
evaluated by assessing EGF-dependent focal transformation
(Fig. 3E–H). EGF induced a concentration-dependent formation
of foci (Fig. 3E, F) that was inhibited by incubation of cells in the
presence of sFRP-3 containing medium (Fig. 3G, H).
sFRP-3 specifically inhibits acute, EGF-induced changes in
Ca2+ homeostasis
The above results suggest that sFRP-3 interferes with the EGF
signaling pathway. To test whether the interaction may be direct,
we investigated a rapid effect of EGF, i.e. increases in [Ca2+]i that
are transient and occur within seconds after growth factor
administration [15]. T17 cells were loaded with the Ca2+-sensitive
dye fura-2, and peak [Ca2+]i variations induced by increasing
concentrations of EGF in the presence of medium conditioned by
either sFRP-3-expressing or not expressing (control) cells were
recorded. As shown in Figure 4A, the medium conditioned by
sFRP-3-expressing cells, but not the control medium, inhibited the
EGF-induced [Ca2+]i increases. These cells exhibit [Ca
2+]i
responses also when stimulated with PDGF and FGF, the P2Y
receptor agonist UTP, the endo-sarcoplasmatic reticulum Ca2+
pump inhibitor thapsigargin or the Ca2+ ionophore ionomycin
[15]: [Ca2+]i increases induced by these molecules were not
affected by sFRP-3 conditioned medium, indicating that the effect
on the EGF evoked response is selective (Fig. 4B).
We then checked if sFRP-3 might affect EGF-induced
phosphorylation of key signal transduction proteins in vitro. As
shown in panel A of Figure S1, the addition of sFRP-3-CM to
NIH-3T3 cells during EGF stimulation reduced both AKT and
MAPK phosphorylation, further indicating that sFRP-3 interferes
with EGF signaling pathway. This reduction was not observed in
the case of bFGF stimulation (Fig. S1B).
sFRP-3-EGF Antagonism
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Figure 1. sFRP-3 modifies cytoskeleton and reduces proliferation of C3H10T1/2 fibroblast. Morphology of C3H10T1/2 cells infected with
vectors expressing puro cDNA (A), sFRP-3 cDNA (C), Wnt-1 cDNA (E). When stained for F-actin with falloidin (see Materials and Methods) both control
cells (B) and Wnt-1 expressing cells (F) showed well organize stress fibers, whereas sFRP-3 expressing cells (D) showed membrane ruffles, filopodia
and disorganized actin fibers. (G) Growth curves for control, Wnt-1 and sFRP-3 expressing cells. Cells were plated at an initial density of 26104 cells/
60 mm dish in DMEM 5% FCS and re-fed on day 2 and 4. Cell numbers were measured by detaching cells with trypsin and counting triplicate samples
sFRP-3-EGF Antagonism
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sFRP-3 reverts EGF-induced inhibition of hair follicle
formation in the embryonic ectoderm
We then tested the ability of sFRP-3 to counteract also one
complex biological activity of EGF in vivo. In the embryonic
ectoderm, hair follicles form at E14.5 dpc: this process also occurs
in tissue explants in vitro and EGF is known to inhibit follicle
appearance when added to the culture medium [16]. In ectoderm
explants grown in control medium we observed the appearance of
numerous hair follicles (arrows in Fig. 5A). This was not the case in
the presence of EGF (Fig. 5B). sFRP-3 alone did not influence
follicle appearance (Fig. 5C) but it reverted EGF-induced
inhibition of hair follicle (Fig. 5D) so that the number of follicles
that formed in the presence of both molecules was similar to that
formed in medium alone.
These data clearly demonstrate that sFRP-3 blocks all the
biological actions of EGF on proliferation, cell signaling, and
morphogenesis that we have tested.
EGF blocks specifically the effect of sFRP-3 in Xenopus
embryos
We then tested whether EGF may conversely interfere with the
effects of sFRP-3. sFRP-3 mRNA injection in Xenopus embryos
inhibits trunk elongation and skeletal muscle formation [8]. We first
demonstrated that mouse sFRP-3 is able to induce the same effect as
the Xenopus homolog (Fig. 6A, B). We then co-injected sFRP-3 and
EGF mRNAs into four cell stage Xenopus embryos: the results of
this experiment showed a reversion of sFRP3-induced phenotype in
most of the co-injected embryos (Fig. 6C). Using a 2-fold excess of
Figure 2. sFRP-3 inhibits proliferation induced by EGF. (A–D) Effect of growth factors on sFRP-3 expressing C3H10T1/2 cells. Growth curves of
C3H10T1/2 cells (A) and sFRP-3 expressing C3H10T1/2 (B) cultivated in 2% horse serum (HS)6specific growth factors. Cells grown in 20% FCS or 2%
HS alone represented positive and negative control respectively. At the time points indicated, cells were fixed and stained with 0.1% crystal violet
solution as described in the Materials and Methods. Dose-dependent effect of EGF on control (C) and sFRP-3 expressing C3H10T1/2 cells (D).
doi:10.1371/journal.pone.0002471.g002
for each point. (H) C3H10T1/2 cells stably transfected with sFRP-3, Wnt1 expression vector or empty vector as control (C), maintained in DMEM 10%
FCS, were starved in DMEM serum free medium. After 24 serum was added again to the medium and cells analyzed for their DNA content by flow
cytometry after Propidium Iodide, staining after 0, 18 and 20 h. Representative plots are shown in the upper panel for the three cell lines at t0 (upper
plots) and t18 (lower plots).
doi:10.1371/journal.pone.0002471.g001
sFRP-3-EGF Antagonism
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EGF mRNA concentration (4 ng sFRP-3 and 8 ng EGF) the rate of
shortened embryos was significantly reduced (from 65,3% shortened
embryos n=149, to 9,9% n=127, as shown in Fig. 6K). Staining of
sFRP-3-injected embryos with anti-sarcomeric myosin antibody
revealed a drastic reduction of the parietal muscles and disruption of
the myotome pattern in comparison with control, un-injected
embryos (Fig. 6D, E, G, H). However, co-injection of sFRP-3 and
EGF mRNAs caused a recover of the chevron like organization of
the trunk/tail skeletal muscle and fully restored parietal muscles
differentiation (Fig. 6F and 6I).
Figure 3. sFRP-3 inhibits proliferation EGF-dependent foci formation. (A–D) sFRP-3 inhibits the EGF-induced colony formation and focal
transformation of EGF-receptor over-expressing NIH 3T3 cells. EGF-dependent cell growth in soft agar. NIH3T3 clone 17 cells suspended in agar
containing normal medium and treated with either 100 ng/ml (A) or 50 ng/ml (B) of EGF formed clearly visible colonies. The effect of EGF was
inhibited in cells suspended in agar containing a 1:1 mixture of normal medium and sFRP-3-containing medium (CM) (C) or the sFRP-3-CM alone (D).
Photographs were taken after 20 days of growth at 26magnification. Insert in D shows a 206magnification of one colony; insert in H shows the
results obtained by counting the colonies in 3 independent, reproducible experiments6SE. Error bars represent s.e.m. Triple asterisks, P,0.001 vs
EGF. (E–H) EGF-dependent focal transformation. NIH3T3 clone 17 cells cultured for 10 days in normal medium containing 100 ng/ml EGF (E) or 50 ng/
ml EGF (F) formed foci. This focal transformation was inhibited incubating the cells in a 1:1 mixture of normal medium and sFRP-3-CM (G) or the sFRP-
3-CM alone (H). Photographs were taken after 10 days of growth at 106magnification. Insert in H shows the results obtained by counting foci in 3
independent, reproducible experiments6SE. Error bars represent s.e.m. Triple asterisks, P,0.001 vs EGF.
doi:10.1371/journal.pone.0002471.g003
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In order to prove the specificity of this interaction we tested the
ability of mFGF8 [17] to revert sFRP-3 phenotype. As reported
[18], XeFGF mRNA injection induces embryo posteriorization
(2 pg, data not shown), with a lack of anterior structure such as
head and eyes. The same phenotype was observed when we co-
inject mFGF-8 with sFRP-3 coding mRNAs (4 ng and 8 ng
respectively), together with the sFRP-3-induced shortening of the
embryo (Fig. 6J), indicating that mFGF-8 is not able to revert the
sFRP-3 phenotype. Thus we can conclude that the recovery of
shorten embryo injected by sFRP-3 mRNA is EGF specific. These
results show that the interaction between sFRP-3 and EGF occurs
also in vivo in Xenopus embryos.
EGF reverts sFRP-3-induced inhibition of axis truncation
and somitic myogenesis in the mouse embryo
We previously showed that sFRP-3 reversibly inhibits myogen-
esis in explants of pre-somitic mesoderm of mouse embryos [19].
We therefore differentiated explant cultures of pre-somitic
mesoderm (with its associated neural tube and surface ectoderm)
in the presence of sFRP-3 conditioned medium and increasing
concentration of EGF. Differentiated, myosin positive, muscle cells
were observed in control explants (not shown) but not in explants
cultured in the presence of sFRP-3 (Fig. 7A). EGF (which by itself
had no effect: not shown) caused dose-dependent reappearance of
differentiated, myosin positive myocytes (Fig. 7B–D). Thus EGF
reverts sFRP-3-induced inhibition of somitic myogenesis. We had
also shown [20] that trans-placental delivery of sFRP-3 caused an
axis truncation in the mouse embryos similar to what observed in
Xenopus, similarly inhibiting skeletal myogenesis. To test whether
these effects could also be reverted by EGF, we performed
transplacental delivery of the two proteins throughout simulta-
neous injection of WOP cells that stably expressed either sFRP-3
or EGF. As previously demonstrated, sFRP-3 delivered at the
onset of the materno-fetal circulation induced a significant axis
truncation (compare Fig. 7F, G with 7E) that what reversed when
we co-injected WOP cells that express sFRP-3 together with WOP
cells that express EGF: in such a case 75% of the embryos display
normal morphology (Fig. 7J–L). Importantly, sFRP-3 phenotype
could not be rescued by the injection of FGF8-expressing WOP
cells (Fig. 7H, I), indicating that EGF reverts morphogenetic
alterations induced by sFRP-3 in a specific manner, also in vivo.
Similarly, in vivo inhibition of myogenesis by sFRP-3 was reverted
by EGF but not by FGF8 (data not shown).
EGF-mediated inhibition of sFRP-3 is Wnt-independent
As sFRP-3 is a known inhibitor of Wnts, the possibility exists
that EGF blocks its activity by stimulating the expression of Wnts
in target cells. To test this hypothesis, we analyzed the expression
of Wnts in C3H10T1/2 cells, embryonic skin and somites explants
cultured for 24 h in vitro in the presence of EGF. To this aim, we
used a PCR array kit containing 84 Wnts and Wnt-pathway genes
(SuperArray Bioscience Corporation, see Materials and Methods
for details). All Wnt genes tested are expressed at very low level in
C3H10T1/2 cells, skin and somites explants (Fig. 8, panels A, B,
C). Moreover, none of the Wnt genes are induced upon 24 h of
EGF stimulation. Indeed, very few genes of this family are
modulated upon EGF stimulation, mostly in a down-regulation
manner (Fig. 8D; see Table S2 for complete C3H10T1/2 array
results, n/a for skin and somites explants). We can thus conclude
that the EGF-mediated inhibition of sFRP-3 observed in vivo is
Wnt-independent, suggesting a direct interaction between EGF
and sFRP-3 molecules.
sFRP-3 binds EGF in vitro
We tested the ability of sFRP-3 to bind EGF in vitro by
performing co-immunoprecipitation (co-IP) experiments. For this
purpose, sFRP-3-HA protein was first immunopurified with an
anti-HA affinity matrix (Covance) from the conditioned medium
(CM) of 293T cells transfected with sFRP-3-HA plasmid and then
incubated with recombinant EGF, followed by the addition of a
non-cleavable, cross-linking reagent (DTSSP). The putative cross-
linked complexes were then analyzed by SDS-PAGE. As shown in
Figure 9A, we detected a clear cross-linked sFRP-3-HA/EGF
complex with anti-EGF antibody only when EGF was incubated
with the sFRP-3-HA protein (lane 6). The molecular weight of this
complex (arrow in panel A) corresponded to the expected mass of
sFRP-3-HA protein (37 KDa, upper band in lane 2) plus EGF
protein (6 KDa, lane 3). The presence of a second band of lower
molecular weight in the immunopurification (20 KDa, lower band
in lane 2) might correspond to a partial degradation of sFRP-3-HA
protein. Notably, also this product forms a complex of higher
Figure 4. sFRP-3 inhibits the EGF-induced [Ca2+]i variations in
EGFR-T17 cells. Fura-2 loaded cells, suspended in KRH medium, were
incubated with medium conditioned (CM) either by sFRP-3-expressing
or not expressing cells, and challenged with increasing concentrations
of EGF (A), or submaximal concentrations of FGF (10 nM), PDGF (1 nM),
UTP (10 mM), thapsigargin (Tg, 10 nM) or iomomycin (Iono, 1 mM) as
indicated (B). Shown are the [Ca2+]i changes6s.e.m. measured as %
increases over resting [Ca2+]i values (n = 4). These were 136612 nM and
were not changed by the addition of sFRP-3 CM or control CM.
doi:10.1371/journal.pone.0002471.g004
sFRP-3-EGF Antagonism
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molecular weight in the presence of EGF (lane 6, arrowhead in
panel A), indicating that it is specifically recognized by the anti-
EGF antibody. We next performed a direct in vitro binding
experiment between EGF and purified sFRP-3 by incubating
sFRP-3-HA or HA peptide with increasing amount of EGF.
Following DTSSP cross-linking, the resulting complexes were
analyzed by Western Blot with the anti-HA antibody. Figure 9B
shows that EGF binds sFRP-3 directly in vitro, giving rise to the
same sFRP-3-HA/EGF complex previously described (arrow in
panel B, lanes 1–4). The amount of sFRP-3-HA/EGF complex
increased with increased EGF concentration. We also detected a
second complex of approximately 75 kDa which could be
explained by the ability of sFRP-3 protein to form dimers, as
previously described [21]. Similarly to the smaller one, the amount
of this second complex appears to be EGF dose-dependent,
suggesting that EGF could induce sFRP-3 dimerization. DTSSP
cross-linking demonstrates in vitro short range interaction between
molecules but does not mimic a natural embryonic environment.
To address this issue, heparin beads (mimicking heparan sulfate)
were loaded with EGF and then incubated with increasing amount
of sFRP-3-HA conditioned medium. The presence of bound
sFRP-3 was then analyzed by western blot as described before.
Figure 9C shows that sFRP-3 binds specifically to EGF in a dose-
dependent manner (lanes 1–4), while neither FGF8-loaded nor
control beads are able to bind sFRP-3 (lane 5 and 6, respectively).
To better understand the nature of the two proteins interaction,
we performed binding experiments using luminescence spectrom-
etry. The EGF/sFRP-3 interaction was studied by measuring
changes in the absorbance spectrum of Alexa488-conjugated EGF,
which gives stable and reproducible absorbance spectrum [22], in
the presence of increasing amount of recFRP3. Addition of sFRP-
3 to EGFAlexa488 caused a significant change in the EGFA-
lexa488 spectrum, i.e. a decrease in the absorbance value, in
particular at emission peak = 517 nm (Fig. 9D, E). Interestingly,
this decrement appeared to be sFRP-3 dose-dependent, as it
diminished at increasing amount of sFRP-3 (Fig. 9D). To test the
specificity, we performed a competition assay by adding native
EGF (at a 10 fold molar excess) to EGFAlexa488 prior to the
addition of sFRP-3 (at a 4 fold molar excess). In these conditions,
the EGFAlexa488 absorbance value decreased of approximately
10 units at emission peak in the presence of sFRP-3, whereas it
diminished of 7 units when native EGF was added before sFRP-3
(Fig. 9E). This difference likely depends upon a competition
between the two types of EGF molecules for sFRP-3 binding,
supporting the specificity of EGF/sFRP-3 interaction.
Membrane-anchored sFRP-3 confers EGF binding to CHO
cells
We finally tested the ability of sFRP-3 to bind EGF in the extra-
cellular space. For this experiment, we generated a fusion protein
in which FRP-3-HA was exposed to the extra-cellular compart-
ment and anchored to the plasma membrane via the fused CD4
trans-membrane moiety. CHO cells, that lack EGF receptor [23],
were transiently transfected either with pCS2FRP3-HACD4 or
pTWEENFRP3-HACD4 constructs that contain the FRP3-HACD4
DNA sequence downstream the CMV promoter, or upstream the
PGKEGFP cassette, respectively. Cell surface expression of the
FRP3-HA- or FRP3-GFP- fusion protein was confirmed by
immunofluorescence staining with anti-HA antibody (Fig. 10A, C)
or GFP expression (Fig. 10D, F). Specific binding of EGF in the
extra-cellular space was then tested by incubating CHO
transfected and control cells with Alexa488-conjugated EGF
Figure 5. sFPR-3 and EGF reciprocal antagonism on hair follicle development. (A–D) sFPR-3 antagonizes the EGF effect rescuing the hair
follicle formation in an organ culture of developing mouse skin. Ectoderm explants growth for 48 hours in control medium (A) or in control medium
supplied with 7 mg/ml sFRP-3-HA (C), showing normal hair follicles differentiation (black arrows). (B) Ectoderm explants growth in organ culture in
medium supplied with 100 ng/ml recombinant EGF for 48 hours, lacking hair follicle differentiation. (D) The co-treatment with EGF and sFPR-3 rescue
the hair follicle formation (black arrow).
doi:10.1371/journal.pone.0002471.g005
sFRP-3-EGF Antagonism
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(Fig. 10B, C). Staining with anti-HA antibody in combination with
direct visualization of EGFAlexa488 (Fig. 10C) on control and
transfected cells revealed co-localization of HA and EGFAlexa488
at membrane surface of one out of four transfected cells (arrow),
but in none of control cells. Alternatively, pTWEENFRP3-HACD4
transfected cells (Fig. 10D) were incubated with a recombinant
mouse EGF followed by the addition of the non-cleavable, cross-
linker DTSSP. Staining with anti-EGF antibody (Fig. 10E) in
combination with direct visualization of GFP showed that in this
case virtually all transfected cells bind EGF in the extra-cellular
space (Fig. 10F). A single FRP-3/GFP positive cell binding EGF
on the surface is shown at high magnification in Fig. 10G–I. The
higher number of FRP-3 expressing cells that bind EGF on the cell
surface in the presence of the DTSSP cross-linker is a strong
indication of a low affinity interaction.
Discussion
The elucidation of the sequence of sFRP proteins immediately
suggested their possible function. A highly conserved, cystein rich
domain (CRD), presumed to bind Wnts, in the absence of a trans-
membrane domain represents the structural requirement for a
dominant negative molecule. It was thus suggested that sFRP-3 may
sequester Wnts in the extra-cellular space and prevent binding to the
Frizzled membrane receptors [8]. How this may occur in molecular
terms is not yet completely understood but the recent elucidation of
sFRP-3 crystal structure led to identify a Wnt-binding site in the
CRDs exhibiting a conserved dimer interface that may be a feature
of Wnt signaling [24]. Indeed, all the initial reports describing the
biological effects of sFRP-3 in different developmental processes
supported this hypothesis [8,20,25,26]. However, it was recently
reported that sFRP-3 unexpectedly increased osteoblast differenti-
ation through a b-catenin-independent pathway in addition to its
previously known function as a decoy receptor for Wnts [27].
The novel and unforeseen finding reported here is the
antagonism between sFRP-3 and EGF. While studying the effects
of sFRP-3 on mouse fibroblasts expressing Wnt-1, we noticed that
sFRP-3 also inhibited proliferation of control fibroblasts that do
not express Wnt-1 or any other Wnts at significant levels. We thus
wondered whether sFRP-3 could exert its inhibitory effect by
interfering with response to different growth factors. The results
clearly indicated that sFRP-3 expressing cells did not proliferate in
response to EGF while responding to the other growth factors
exactly as their control counterparts. The specificity of the
interaction between sFRP-3 and EGF was assessed further in
another cell type, NIH-3T3 cells, where we could test a specific
acute effect induced by these growth factors, i.e. the increase in
[Ca2+]i [15]. sFRP-3 was found to selectively counteract the effect
of EGF on [Ca2+]i increases, while not affecting the increase in
[Ca2+]i induced by FGF, PDGF or other stimuli that modify
[Ca2+]i. This confirmed the specificity of interaction and also
showed that the effect is probably direct since it acts in a period of
few seconds, leading to inhibition of downstream transduction
effectors. There is abundant evidence of multiple cross-talks
Figure 6. EGF specifically antagonizes sFPR-3 effects in Xenopus embryos. (A) Lateral view of a normal embryo at stage 28/29 NF un-injected.
(B) Embryo injected with 4 ng of mouse sFPR-3 mRNA at stage 28/29 NF, showing a remarkable shortened of the trunk and the tail and a reducedmuscle
differentiation. (C) Rescue of the shortened phenotype by co-injection of 4 ng of sFPR-3 and 8 ng of EGF mouse mRNAs. (D–I) Whole mount
immunostaining with 12–101 specific amphibians muscle monoclonal antibody, peroxidase detected. (D) Normal embryo un-injected at stage 35/36 NF,
showing black labeling in the trunk and tail muscles and in the parietal muscle (black arrow). (E) Injected embryo withmouse sFPR-3mRNA at stage 35/36,
presenting a shortened trunk and a kinky tail; furthermore the parietal muscles (black arrow) are remarkably reduced. (F) Rescue of the shortened kinky
phenotype, showing completely restored muscle differentiation also in the parietal muscle (red arrow). (G–I) High power magnification respectively of D–
F, showing in detail the chevron like organization of the tail muscles of un-injected normal larvae (G), missing in the sFRP-3 treated tadpole tail (H) and
restored in the co-injected larvae with EGF mouse mRNA (I). (J) Lateral view of a co-injected embryo with 4 ng of sFRP-3 and 8 ng of FGF-8 mouse coding
mRNAs, showing no rescue of the sFRP-3 phenotype. (K) Quantization of multiple injections (n=3) showing the rate of the phenotype rescue by co-
injection with 8 ng of EGF mouse mRNA after the injection of sFPR-3 (asterisk indicates statistical significance P,0.001).
doi:10.1371/journal.pone.0002471.g006
sFRP-3-EGF Antagonism
PLoS ONE | www.plosone.org 8 June 2008 | Volume 3 | Issue 6 | e2471
between the EGF and the Wnt signaling pathways both in
Drosophila and in vertebrates [28–34]. However this is the first
evidence of a direct effect of sFRP-3 on EGF activity in
mammalian cells.
Because of this novel observation, we investigated whether other
biological activities of EGF could be neutralized by sFRP-3. Under
certain conditions EGF induces morphological transformation and
adhesion independent growth of mouse cells. When mouse 3T3
fibroblasts over-expressing the EGF receptor are exposed to EGF
they acquire the ability to grow in soft agar and to form
transformed foci on plastic. Both these activities were completely
abrogated by sFRP-3 in a dose-dependent fashion. We then tested
EGF-sFRP-3 interaction in a morphogenetic assay where EGF
inhibits hair follicle development that occurs spontaneously in
organ cultures of embryonic ectoderm. Strikingly, sFRP-3 reverted
this inhibitory activity by causing the appearance of a normal
number of follicles in the presence of EGF, without any effect on
its own. Thus, all the biological activities of EGF that we have
tested are blocked by sFRP-3 in a dose dependent way. However,
EGF may induce synthesis of some Wnt in target tissues and thus
Figure 7. EGF reverts sFRP-3-induced inhibition of somitic myogenesis. (A–D) EGF reverts sFRP-3-induced inhibition of somitic myogenesis
in explant cultures. MyHC antibody staining on explants cultures of presomitic mesoderm from E9.5 Myf5a2 embryos in the presence of sFRP-3 and
EGF proteins. Mesoderm differentiation, which is almost completely abolished in the presence of sFRP-3 protein (A), is partially to fully restored when
increasing amount of EGF are added to the culture (B–D: 50, 100 and 200 ng/ml), as revealed by the increasing number of positive MyHC fibers. (E–M)
EGF rescues inhibition of myogenesis induced by sFRP-3 in vivo. (F,G) Transplacental delivery of s-FRP3 causes severe malformations of the caudal
region of injected embryos. (J–L) Normal embryo morphology is restored when sFRP-3 is co-injected together with EGF, but not with FGF (H; I). (E)
Control not-injected embryo. (M) Quantification of injected embryos with their relative phenotype in 3 independent, reproducible experiments.
doi:10.1371/journal.pone.0002471.g007
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the inhibition by sFRP-3 would be explained by its canonical
action on EGF-induced Wnt genes. Several indirect evidence
argue against this possibility: (i) sFRP-3 inhibits EGF-stimulated
Ca2+ uptake in a time-frame that precludes induction of Wnt
transcription, translation and secretion; (ii) in the Xenopus
experiments, EGF injection alone did not cause axis duplication.
Nevertheless, this possibility was formally ruled out by a detailed
analysis of Wnt family genes expressed by 10T1/2 fibroblasts,
ectoderm and somite explants which revealed that none of the 84
genes tested was induced by EGF.
On the other hand, the inhibition by sFRP-3 on EGF effects
could be explained by their direct interaction or by sFRP-3
binding to EGF receptor.
As a matter of fact, EGF protein is expressed in the neuro-
ectoderm and in the mesoderm contiguously to regions where the
sFRP-3 messanger is expressed: these include a ventral area of the
neural tube, the myotome and dermomyotome in somites and a
proximal area of the developing limbs (see Fig. S2). Testing this
hypothesis by classic knock out or morpholino loss of function
experiments is complicated by the fact that the effects of either
sFRP-3 or EGF cannot be analyzed separately from interaction
with their primary ligands. In fact, blocking sFRP-3 by Xenopus
morpholino injection experiments show a disorder in Wnt’s
pathways. The injected embryos present eye and fore brain
disorder due to the lacking of antagonism (sFRP-3) to inhibit the
posteriorizing effects of Wnt’s signals (see Fig. S3), as already
demonstrated in Xenopus and other vertebrates for several Wnt’s
antagonists [35–38]. However, in the Xenopus ectoderm, where
Wnts are not known to be expressed, ablation of sFRP-3 caused a
delay in the cement gland differentiation (see Fig. S4). This
adhesive organ, that allows the Xenopus embryo to attach to
objects in the water by secreting mucus, arise from the ectoderm
that forms a pseudo-stratified columnar epithelium expressing
cytokeratins by stage 28/29 NF [39]. Thus, the delay in ectoderm
differentiation induced by ablation of sFRP-3 during the cement
gland development suggest a role of sFRP-3 in regulating EGF-
induced proliferation that maintains the ectoderm in an
undifferentiated state.
Moreover, in gain of function experiments, we show that in the
large majority of sFRP-3 treated embryos co-injection of EGF can
restore a normal axis, whose elongation is blocked by sFRP-3. In the
mouse embryo, where sFRP-3 affects axis elongation similarly to its
effect in Xenopus [20], the concomitant transplacental delivery of
both sFRP-3 and EGF (but not of FGF8) restored a normal embryo
morphology in the majority of the embryos and also restored sFRP-
3-dependent inhibition of myogenesis as it does in vitro.
All these data indicate a reciprocal interference between sFRP-3
and EGF in all the assays that we have used, both in Xenopus and in
mouse. The most likely explanation for these phenomena is a physical
interaction of the two proteins, possibly involving their CRD.
Examples of non canonical protein-protein interaction have
been reported to play a significant if not a major role in tissue and
organ morphogenesis. For example, the Cerberus protein
functions as a multivalent growth factor that antagonizes Nodal,
BMP and Wnt proteins by direct interaction in the extra-cellular
space, via independent binding sites [40]. Also, Chordin
Figure 8. Wnts expression profile in C3H10T1/2 and embryonic
explant cultures. Wnt genes expression in C3H10T1/2 fibroblast
(panel A), somites (panel B) and embryonic skin (panel C). Histograms
represent the relative expression level for each gene in control (red
bars) and EGF-treated (blue bars) samples, as calculated with the 2^
(2D Ct) formula in comparison with the housekeeping genes
Hsp90ab1, Gapdh and Actb (see Materials and Methods for details).
(Panel D). EGF-modulated genes in C3H10T1/2 fibroblast, somites and
embryonic skin. For genes description, see Table S2.
doi:10.1371/journal.pone.0002471.g008
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antagonizes signaling by bone morphogenetic proteins (BMPs) by
blocking binding to their receptors. Chordin, which is able to
dorsalize mesoderm and to neuralize ectoderm, binds to BMP-4
with high affinity but not to activin or TGF-b1 [41]. Very recently
it was shown that PDGFbb binds to the VEGF receptors and
affects VEGF-dependent in vitro proliferation [42].
Therefore, this newly described interaction is not unprecedented
but still raises questions on its possible significance during vertebrate
embryogenesis. It should be noted that the binding affinity is low,
which made it difficult to document specificity, but this fact has
probably a significance. We propose that a low affinity binding for a
relatively abundant molecule such as sFRP-3 may represent a way to
prevent ligand diffusion outside of its domain of action.
It is important to underline that in Drosophila morphogenesis
many fate choice decisions are dictated by a competition between the
Wg and the EGFR signaling pathways. For example, cells in the
Drosophila eye are resistant to apoptosis induced by activated
Armadillo for a long period prior to the onset of cell death at themid-
pupal stage. This latency is due to EGF receptor (EGFR)/MAP
kinase signaling since when it naturally ceases, the cells rapidly die.
Thus, activated Armadillo is subject to a specific negative control by
EGFR/Rolled MAP kinase signaling [43]. Furthermore, in the
ventral epidermis Wingless signaling specifies smooth cells that
produce naked cuticle, whereas the activation of the Drosophila
epidermal growth factor receptor (DER) leads to the production of
intercalating cells with cytoplasmic extrusions known as denticles.
The DER pathway promotes denticle formation by activating svb
expression that is known to induce, cell autonomously, cytoskeletal
modifications producing the denticles [33]. Conversely, Wingless
promotes the smooth cell fate through the transcriptional repression
of svb by the bipartite nuclear factor Armadillo/dTcf. Moreover
recent findings show the existence of a cortical region (cortical
antihem) in which EGF family members and the secreted Wnt
antagonist sFRP-2 are co-expressed [44].
Figure 9. sFRP-3 binds EGF in vitro. (A) Co-IP of sFRP-3-HA and EGF. Supernatant from 293 cells transfected with control plasmid (lanes 1, 4) or
purified sFRP-3-HA (lanes 2, 5, 6) were incubated with mouse recEGF (lanes 4, 6), DTSSP cross-linked and analysed under non-reducing conditions.
Western blot analysis with anti-HA (lanes 1, 2) and anti-EGF antibodies (lanes 3–6) revealed the presence of EGF bound to sFRP-3-HA (lane 6), but not
in the control sample (lane 4). Note that the shift in molecular weight of the band(s) corresponding to sFRP-HA (lane 2) is due to EGF binding (arrow
and arrowhead in lane 6). Free mouse recEGF was used as positive control for the immunoblot (lane 3). (B) Dose-dependent binding of EGF to sFRP-3.
In vitro binding of increasing amount of EGF (100 ng, 200 ng, 400 ng and 600 ng,) to sFRP-3-HA (100 ng), followed by DTSSP crosslinking and
revealed by Western blot analysis with anti-HA. The amount of EGF/sFRP-3 complexes (lanes 1–4) correlates with the increasing amount of EGF. As
control for binding specificity, 100 ng of sFRP-3-HA alone (lane 5, not detectable) were cross-linked and revealed as before. (C) In vitro binding of
sFRP-3 to EGF-loaded heparin beads. Western blot analysis with anti-HA on proteins adsorbed on EGF-loaded (lanes 1–4), FGF8-loaded (lane 5) and
control beads (lane 6), following incubation with increasing amount of sFRP-3-HA supernatant (5–50 ml). sFRP-3 binds specifically to EGF, in a dose
dependent manner. (D) Binding affinity of EGF for sFRP-3. EGFAlexa488 fluorescent absorbance at emission peak (517 nm) decreases in relation of
increasing amount of sFRP-3. (E) Competition assay. Absorbance scanning from emission value 505 nm to 540 nm of EGFAlexa488 (green curve). A
decreasing of the emission peak (517 nm) is shown in relation to EGFAlexa488/sFRP-3 interaction (red curve). By adding native egf to EGFAlexa488
prior to the incubation with sFRP-3, the absorbance reduction of the emission peak was smaller (blue curve).
doi:10.1371/journal.pone.0002471.g009
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The identification of a sFRP-3/EGF interaction in vertebrate
development outlines a previously unknown developmental
mechanism; it also opens a new area of investigation on the
specific role of such interaction in the development of vertebrate
neuroectoderm and mesoderm.
Materials and Methods
Cell culture and proliferation assay
C3H10T1/2 fibroblasts, Bosc23 packaging cells, 293FT and
NIH 3T3 cells overexpressing the EFG receptor (clone 17, 46105
receptor/cells) were grown in Dulbecco’s modified Eagle’s
medium (DMEM) (Gibco), supplemented with 10% fetal calf
serum (FCS, Gibco). CHO cells were grown in a-MEM (Gibco)
supplemented with 10% FCS.
To measure proliferation, 800–1200 cells/well were plated in 96-
well plates and kept overnight in DMEM containing 2% horse
serum, before shifting the cells to the same medium supplemented
with the specific growth factor (day 0): EGF (100 ng/ml, Sigma),
bFGF (10 ng/ml), PDGF-BB (0.4 nM) or HGF (20 ng/ml). The
culture medium was changed every 48 hours. At different times, cells
were fixed and stained in 0.1% crystal violet solution in 200 mM 4-
morpholinoethanesulfonic acid, pH 6. Cell number was calculated
from a calibration curve (cell number/OD 600 nm) done under the
same conditions [45]. In another set of experiments 106 C3H10T1/
2 cells, wt or expressingWnt1 or sFRP-3 (see below), and maintained
in DMEM 10% FCS, were starved in DMEM serum free medium.
After 24 serum was added again to the medium and cells analyzed
for their DNA content by flow cytometry after Propidium Iodide
staining, after 0, 18 and 20 h.
Conditioned medium (CM) was prepared as described [8].
Briefly, 293FT cells were transiently transfected with sFRP-3-HA
plasmid and culture medium was collected from cells 5 days after
transfection. For cell culture experiments CM was used undiluted
(SFRP3 100%) or diluted 1:2 with culture medium (SFRP3 50%),
and additionated with growth factors prior to be added to cells.
Western blot analysis
Western blot analysis was performed as described [46], using the
following antibodies: tubulin B-5-1-2 (Zymed); HA (Babco); EGF
(Sigma); AKT; P-AKT; MAPK; P-MAPK (Cell Signalling).
Reactive proteins were detected with horseradish peroxidase-
conjugated secondary antibodies and visualized with the enhanced
chemioluminescence detection Kit (Amersham International PLC).
Growth in soft agar and foci formation
Growth in soft agar and foci formation efficiency of NIH 3T3
cells clone 17 cells in the presence of increasing concentration of
EGF (Calbiochem) in presence or absence of sFRP-3 conditioned
medium were evaluated according to [47].
[Ca2+]i measurement
NIH 3T3 clone 17 cells were suspended in KRH medium [15]
at pH 7.4 and loaded with the Ca2+-sensitive dye, fura-2, for
30 min at 25uC and kept at 37uC until use. The experiments were
initiated by incubating cell aliquots (26106 cells in 750 ml) with
Figure 10. Membrane-anchored FRP-3 binds EGF at the cell surface. (A–C) Antibody staining for HA (in red, A,C) in CHO cells transfected with
pCS2FRP3-HACD4 shows FRP-3 expression on the cell surface. Upon administration of EGFAlexa488, EGF expression (green) is detectable only on
whole intact CHO cell expressing FRP-3, but not on control cells (C). Star in panel B shows non-specific EGF binding on necrotic cell. Double labelling
for HA and GFP shows co-localization of FRP-3 and EGF at the cell surface (arrow in C). (D–I) Anti-EGF antibody staining (in red) on FRP-3GFP CHO cells
transfected with pTWEENFRP3-HACD4. (D–F) Upon DTSSP cross-linking all CHO cells that express FRP-3CD4 (green staining in D) bind EGF at the
membrane surface (red staining in E and merged colour in F). (G–I) 406magnification of a single CHO cell that expressed FRP-3GFP (in green) and
bind EGF (in red). Double labelling for GFP and anti-HA in panel I shows the two proteins interaction occurs at the membrane surface.
doi:10.1371/journal.pone.0002471.g010
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10 ml of medium conditioned either by sFRP-3-expressing or not
expressing cells for 15 min at 37uC. Cells were subsequently
centrifuged and resuspended in KRH supplemented with 250 mM
sulfinpyrazone to prevent dye leakage. To measure the variations
in the intracellular Ca2+ concentration ([Ca2+]i) induced by EGF,
FGF, PDGF, UTP, ionomycin or thapsigargin, the samples were
transferred to a thermostatted cuvette (37uC), maintained under
continuous stirring, and analyzed in a Perkin Elmer LS-50B
fluorimeter as described [15].
EGF pathway activation
NIH 3T3 clone 17 cells were stimulated with EGF or bFGF in
presence or absence of sFRP-3 conditioned medium for 309 or 609.
Phosphorylation of AKT and MAPK was detected by western blot
analysis using P-AKT and P-MAPK specific antibodies.
Retrovirus preparation and viral infection
The mammalian retroviral vector pBABE-puro was used to
construct and express full-length murine sFRP-3 and Wnt-1. sFRP-
3 cDNA was generously provided by L. Leyns [8] and Wnt-1
cDNA by J. Papkoff [48].
Recombinant retroviruses were generated by pEI (polyethyle-
nimine Aldrich 40872-7) transfection of retroviral construct into
Bosc23 packaging cells as previously described [49]. Two days
later the viral supernatants were harvested, filtered and used to
infect the cells for three hours in the presence of 8 mg/ml of
polybrene (Sigma). 24 hr later the cultures were selected in 2 mg/
ml of Puromycin (Sigma). Individual clones were isolated and
expanded.
RNA synthesis
Synthetic capped sFRP-3, EGF and FGF8 mRNAs were
obtained from linearized pCS2mFRZB-HA, pCMV-SPORT6/
EGF (IMAGE clone 4164289, from Open Biosystems) and
pCS2FGF8 [17] plasmids, using the mMESSAGE mMACHINE
kit (Ambion), according to the instruction manual.
Xenopus embryo manipulation and whole mount
immunostaining
Xenopus laevis embryos were obtained by standard procedures
and staged according to Nieuwkoop and Faber (NF) [50], cultured
in Normal Amphibian Medium (NAM) at 24uC. The embryos
were microinjected in one blastomere at 4-cell stage in Petri dishes
coated with 1.5% noble agar and then cultured in NAM/10. For
immunofluorescence and whole mount immunostaining embryos
were treated according to [51]. For muscles labelling we used 12–
101 monoclonal antibody [52] and for cytokeratins labelling we
used Cytokeratins Wide Spectrum (Dako).
Placenta injection of WOP cells
WOP (Without Origin of Polyoma DNA replication) cells were
stably transfected with pCMV-SPORT6/EGF (IMAGE clone
4164289, from Open Biosystems), pcDNA3/sFrzb-3 [20] or
pCS2FGF8 [17] vectors with Fugene (Roche), following the
manufacturer instructions. 56105 cells in 5 ml of PBS were
injected into the maternal side of the placenta through the uterine
wall, as previously described [20]. Usually, one uterine horn of the
embryos at approximate age of E9.5 was injected, in order to
avoid massive embryo abortion.
Explants culture
Pre-somitic mesoderm explants from Myf5a embryos [53] at
E9.5 dpc (20–24 somites) were cultured as previously described
[54,55]. After fixation in 4% paraformaldehyde, explants were
analyzed for myosin heavy chain expression by immunofluores-
cence. Ectoderm explants were obtained from CD1 embryos at
E13.5 as previously described [16]; after culture the explants were
fixed in 4% paraformaldehyde and paraffin sectioned. Skin
sections were stained with standard hematoxylin-eosin coloration
and then analyzed for hair follicle differentiation under the
microscope. For RT-PCR experiments, E9.5 somites and E13.5
CD1 embryonic skin explants were cultured for 24 h in
Dulbecco’s modified Eagle’s medium (DMEM) (Gibco), supple-
mented with 2% horse serum (HS, Gibco) and 100 ng/ml EGF.
Wnt-pathway PCR-array
RNA was extracted from 10T1/2 cells, E9.5 somites and E13.5
ectoderm explants 24 h after culture with or without EGF by using
TRIzol (Invitrogen). Genomic DNA contamination was eliminated
by Dnase treatment by using Rneasy Micro Kit (Qiagen) and RNA
was retro-transcribed by RT2 First Strand Kit (Bioscience
Corporation). Mouse Wnt Signaling Pathway RT2 Profiler PCR
Array (http://www.superarray.com/rt_pcr_product/HTML/
PAMM-043A.html) and RT2 Real-Timer SyBR Green/ROX
PCR Mix were purchased from SuperArray Bioscience Corpora-
tion. PCR was performed on iCycler (Thermal Cycler Biorad), with
the iQ detection system (Biorad). For data analysis theDDCt method
was used; for each gene fold-changes were calculated as difference in
gene expression between control and EGF-treated samples. A
positive value indicates gene up-regulation and a negative value
indicates gene down-regulation. The formula used to calculate the
relative gene expression level (2^ (2D Ct)) is: DCt=Ct (GOI)2avg.
(Ct (HKG)), where GOI is each gene of interest, and HKG are the
housekeeping genes chosen for the ‘‘EGF-Control Gene’’.
Immunofluorescence
Immunofluorescence on cells and mesoderm explants was
performed as previously described [20], using the following
antibodies: HA (Babco), EGF (Sigma), MyHC [56]. Immunoflu-
orescence on mouse cryostat sections was performed as previously
reported [57] using the following antibodies: EGF (Sigma), nestin
(DHSB).
Production of sFRP-3CD4 chimeric protein
Construct for expression of CD4-anchored sFRP-3-HA protein
was prepared as following. The FRP3-HA coding sequence was
PCR-amplified from pCS2mFRZB-HA vector with a forward EcoRI-
flanked primer and a reverse XhoI-flanked primer where the stop
codon was replaced by an AflII site (59-CTACTCGAGACATTT-
CAGGATCTTAAGTCGTACTGGCCGGG-39). The FRP-HA
PCR fragment was then cloned EcoRI/XhoI into pBSK vector.
The trans-membrane domain of the hCD4, flanked by spacer
sequences and containing its stop codon, was PCR-amplified from
pCMV-SPORT6/CD4 with a forward primer containing an AflII
site (59-CTGCTGGAATCCAACCTTAAGGTTCTGCCCACA
TGGTCCA-39) and a reverse XhoI-flanked primer (59-CAGACTC-
GAGGGAGGCTGCAAGTGGG ATCTGCC-39). The CD4
PCR product was AflII/XhoI double digested and then inserted into
pBsFRP-3-HA vector, fused in frame to the COOH-terminus of
FRP-HA. The FRP3-HACD4 fragment was then cloned EcoRI/XhoI
into pCS2 vector, downstream the CMV promoter, or XbaI/XhoI
into pRRL.CMV.cPPT.hPGK.EGFP.WPRE vector [58], upstream
the PGKEGFP cassette. We called these constructs pCS2FRP3-
HACD4 and pTWEENFRP3-HACD4, respectively. Cell surface
expression of CD4-anchored sFRP-3-HA protein was monitored by
immunofluorescence staining with anti-HA antibody or live GFP
expression.
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sFRP-3 protein in vitro purification
sFRP-3-HA protein was produced as previously described [46].
For protein purification, 10 ml of conditioned medium (CM) from
293FT cells transfected with sFRP-3-HA plasmid were incubated
with anti-HA affinity matrix (Covance) for 2 hours at 4uC. After
washing in PBS, biologically active sFRP-3-HA protein was
purified by competitive elution with 1mg/ml HA peptide (Roche).
In vitro binding, chemical cross-linking and Co-IP
1 mg of purified sFRP-3-HA protein was incubated with 1 mg of
recEGF (Sigma) in PBS for 2 hours on a rocker at 4uC. 5 mM
DTSSP cross-linker (Pierce) was then added to the sample and the
reaction mixture was incubated for 1 hr at 4uC. Cross-linking
reaction was quenched by the addition of 20 mM Tris pH 7.5, for
15 min. The cross-linked product was immunoprecipitated with
an anti-HA affinity matrix (Covance) and then resolved on 4–12%
gradient SDS-PAGE (Invitrogen) in non-reducing conditions.
Immunoblot was performed as described above using the following
antibodies: HA (Babco), EGF (Sigma). For dose-dependent
binding experiment, 100 nM purified sFRP-3-HA (200 ng) or
100 nM of Ha peptide (Sigma) was incubated for 1 hr at 4uC with
increasing amount of recEGF (1 mM, 2 mM, 4 mM and 6 mM,
respectively), crosslinked and the complexes were then analysed by
Western blot.
EGF-binding assay
Heparin-immobilized acrylic beads (Sigma) were saturated
overnight at 4uC with 5 mg of either recEGF (Sigma) or recFGF2
(Invitrogen) diluted in PBS 0.2% BSA. As negative control,
heparin beads were incubated in PBS 0.5% BSA. To test whether
sFRP-3 binds specifically to EGF, EGF-loaded beads were
incubated for 2 hours at room temperature with increasing
amount of sFRP-3-HA (5 ml, 10 ml, 20 ml and 50 ml of sFRP-3
conditioned medium), whereas FGF2-loaded and control beads
were incubated with the highest amount of sFRP-3-HA. After 3
washing in PBS, beads were resuspended in 20 ml of lamely buffer,
boiled and loaded onto a protein gel. Western blot analysis for HA
or EGF was performed as described before.
Binding affinity analysis
25 nM of EGFAlexa488 (Molecular Probes) was incubated with
increasing amount (25 nM to 300 nM) of mouse recombinant
sFRP-3 (R&D) in PBS, and then absorbance spectrum of Alexa488
was measured with a luminescence spectrometer LS50B (Perkin
Elmer). The competition assay was performed by adding 250 nM
of native EGF to 25 nM EGFAlexa488 prior to the addition of
100 nM sFRP-3. The absorbance spectrum of Alexa488 was
measured as before.
Supporting Information
Figure S1 sFRP-3 interferes with EGF signaling pathway AKT
and MAPK phosphorylation in NIH-3T3 cells upon EGF
stimulation is reduced in the presence of sFRP-3-CM (A), but
not in the presence of bFGF (B).
Found at: doi:10.1371/journal.pone.0002471.s001 (1.07 MB
DOC)
Figure S2 Tissue distribution of sFRP-3 and EGF in the
developing mammalian embryo (A,B,D,E,G,H) Immunofluores-
cence on cryostat transverse (A–C, G–H, 106magnification) and
parasagittal (D–E, 206magnification) sections of mouse embryos
at E10.5 using EGF (red) and nestin (green) antibodies. A, D, G
show only expression of EGF and DAPI staining (blue), B, E, H
show respectively the same sections as in A, D, G but EGF signal
(red) is merged with the nestin signal (green). Arrow in H points to
few cells in the limb expressing EGF. (C,F,I) In situ hybridization
on cryostat transverse (C, I, 106magnification) and parasagittal
(F, 206magnification) sections of mouse embryos at E10.5 using
sFRP-3 specific riboprobe. C, F, I show sections that are
alternating to those shown in A, D, G. Arrow in F points to
cells in the myotome surrounded by sFRP-3 expressing cells. dn,
dorsal neurons; drg, dorsal root ganglia; li, limb; mn, motorneur-
ons; my, myotome; vz, ventricular zone.
Found at: doi:10.1371/journal.pone.0002471.s002 (8.00 MB
DOC)
Figure S3 sFRP-3 Moprholino Oligo’s injection affects Wnt
pathway. (A–C) Immunofluorescence on stage 28 NF Xenopus
embryo sections against cytokeratins (red) and counterstained by
49,69-diamidino-2-phenylindole (DAPI) blue. (A) Normal wild type
un-injected embryo presenting intense ketatinization on the
cement gland, as revealed by cytokeratins red labeling. (B) sFRP3
morpholino (sFRP3-MO) injected embryo showing an almost
devoid of cytokeratins red labeling on the adhesive organ. (C)
sFRP3-MO/mRNA co-injected embryo revealing restoration of
keratin differentiation in the cement gland. Inserts: high
magnification of the cement gland. (D) Western blott analysis on
crude protein extracts from stage 28 NF Xenopus embryos
showing the decreasing of the cytokeratins production in the
sFRP3-MO treated embryos and its restoration on co-injected
sFRP3-MO/mRNA embryos. The filter was hybridized against
citokeratins (Pan-Cyto) and against laminin as internal control.
Found at: doi:10.1371/journal.pone.0002471.s003 (5.57 MB
DOC)
Figure S4 sFRP-3 ablation affects cement gland differentiation.
(A–C) Immunofluorescence on stage 28 NF Xenopus embryo
sections against cytokeratins (red) and counterstained by 49,69-
diamidino-2-phenylindole (DAPI) blue. (A) Normal wild type un-
injected embryo presenting intense keratinization on the cement
gland, as revealed by cytokeratins red labeling. (B) sFRP3
morpholino (sFRP3-MO) injected embryo showing an almost
devoid of cytokeratins red labeling on the adhesive organ. (C)
sFRP3-MO/mRNA co-injected embryo revealing restoration of
keratin differentiation in the cement gland. Inserts: high
magnification of the cement gland. (D) Western blot analysis on
crude protein extracts from stage 28 NF Xenopus embryos
showing the decreasing of the cytokeratins production in the
sFRP3-MO treated embryos and its restoration on co-injected
sFRP3-MO/mRNA embryos. The filter was hybridized against
cytokeratins (Pan-Cyto) and against laminin as internal control.
Found at: doi:10.1371/journal.pone.0002471.s004 (5.42 MB
DOC)
Table S1 The table shows the percentage of cells in G0/G1, S
and G2/M, at t0, t18 and t20, calculated using the CellQuest
analysis software.
Found at: doi:10.1371/journal.pone.0002471.s005 (0.03 MB
DOC)
Table S2 Expression profile of mouse Wnts signaling pathway
genes in control (CT) and EGF-treated (EGF) C3H10T1/2 cells.
The relative expression level of each gene is given by the 2^2DCt
value (see Materials and Methods for formula calculation). Fold
differences .2 or ,2 between EGF and CT samples are outlined
in green and red, respectively, in the ‘‘Fold-up or down
regulation’’ column.
Found at: doi:10.1371/journal.pone.0002471.s006 (0.19 MB
DOC)
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